ESMO China Voice | Professor Sheng Xinan Reports RENOTORCH Study, Sharing the First “Domestic Innovation” Immune Combination Therapy for First-Line
The combination of immune checkpoint inhibitors and anti-angiogenic therapy has become a first-line treatment option for advanced renal cell carcinoma (aRCC), with previous studies including patients of all IMDC risk levels. During a dedicated session on urological oncology at the 2023 ESMO Congress, Professor Sheng Xinan from Peking University Cancer Hospital, on behalf of a clinical research team, presented the results of the first Phase 3 study focusing on immune combination therapy for high-risk IMDC patients with advanced kidney cancer, making it the first domestic Phase 3 study of first-line immune combination therapy for advanced kidney cancer. The positive results offer a new first-line treatment option for patients with advanced kidney cancer.